These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20661025)

  • 1. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
    Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
    Ondo WG; Perkins T; Swick T; Hull KL; Jimenez JE; Garris TS; Pardi D
    Arch Neurol; 2008 Oct; 65(10):1337-40. PubMed ID: 18852348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A; Lang AE; Shapiro CM
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
    Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
    Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.
    Paus S; Brecht HM; Köster J; Seeger G; Klockgether T; Wüllner U
    Mov Disord; 2003 Jun; 18(6):659-67. PubMed ID: 12784269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
    Rektorova I; Balaz M; Svatova J; Zarubova K; Honig I; Dostal V; Sedlackova S; Nestrasil I; Mastik J; Bares M; Veliskova J; Dusek L
    Clin Neuropharmacol; 2008; 31(5):261-6. PubMed ID: 18836343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug safety evaluation of ropinirole prolonged release.
    Stocchi F; Radicati FG; Torti M
    Expert Opin Drug Saf; 2014 Mar; 13(3):383-9. PubMed ID: 24490799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleepiness in Parkinson's disease: a controlled study.
    Brodsky MA; Godbold J; Roth T; Olanow CW
    Mov Disord; 2003 Jun; 18(6):668-72. PubMed ID: 12784270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease.
    Ray Chaudhuri K; Martinez-Martin P; Rolfe KA; Cooper J; Rockett CB; Giorgi L; Ondo WG
    Eur J Neurol; 2012 Jan; 19(1):105-13. PubMed ID: 21699627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonists and sleepiness in PD: review of the literature and personal findings.
    Manni R; Terzaghi M; Sartori I; Mancini F; Pacchetti C
    Sleep Med; 2004 Mar; 5(2):189-93. PubMed ID: 15033142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
    Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
    Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.
    Badarny S; Stern A; Susel Z; Honigman S; Hocherman S
    Acta Neurol Scand; 2006 May; 113(5):294-300. PubMed ID: 16629764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome.
    Saletu M; Anderer P; Saletu-Zyhlarz G; Hauer C; Saletu B
    Eur Arch Psychiatry Clin Neurosci; 2002 Aug; 252(4):185-94. PubMed ID: 12242580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?
    Gjerstad MD; Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
    Neurology; 2006 Sep; 67(5):853-8. PubMed ID: 16966550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panic attack-like episodes possibly associated with ropinirole.
    Alonso-Navarro H; Jiménez-Jiménez FJ; Pilo-de-la-Fuente B; Plaza-Nieto JF
    Clin Neuropharmacol; 2009; 32(4):237-8. PubMed ID: 19644237
    [No Abstract]   [Full Text] [Related]  

  • 20. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment.
    Kaynak D; Kiziltan G; Kaynak H; Benbir G; Uysal O
    Eur J Neurol; 2005 Mar; 12(3):199-207. PubMed ID: 15693809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.